Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by youngpupperon Mar 26, 2019 11:14pm

103 Views

Post# 29540377

RE:Input appreciated

I just think that any major pharma or even generics company would make the money back on an Antibe buyout within a few years of marketing a better, safer and improved Naproxen. The knock on NSAIDs is the negatives of long-term use and that's why people look for alternatives or suffer side effects. Eliminate that concern and you'll steal current customers and gain new ones that stayed away from NSAIDs.

EV4Lyfe wrote: I have been following this stock for a while now. I bought around 20 cents and sold around 60 cents and kept some. But wasn't a lot of money (as I don't see how someone can put more than a couple percent of their portfolio in this without being able to stomach the potential of losing more than that % of your portfolio) because if this thing doesn't work out isn't it worthless pretty much?

I am wondering why a lot of you think it could be worth 2-5 bucks per share so quickly if all goes well, how could that multiple make sense for anyone to buy the company out?

If someone can show me the math (upside and downside) that would help me decide to add more or not. I always base downside on tangible book per share which would pretty much put this at losing more than 70% of your investment if this doesn't work out. Unless someone has a better, more realistic downside calculation versus my more "doomsday" math.

Thanks,

EV